BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21606209)

  • 1. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
    Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W
    Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
    Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK
    Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required.
    Langendijk JA; Oosting SF
    Ann Oncol; 2011 Oct; 22(10):2157-9. PubMed ID: 21878428
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy.
    Cabezón-Gutiérrez L; Khosravi-Shahi P; Escobar-Álvarez Y
    Oral Oncol; 2012 Apr; 48(4):293-7. PubMed ID: 22137799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
    Teoh DC; Rodger S; Say J; Hartley A
    Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
    [No Abstract]   [Full Text] [Related]  

  • 6. Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191-2200.
    Russi EG; Bensadoun RJ; Merlano MC; Bourhis J; Ricardi U; Giralt J; Pinto C; Budach W; Corvò R; Lacouture ME; Bernier J
    Ann Oncol; 2013 Sep; 24(9):2463-5. PubMed ID: 23897703
    [No Abstract]   [Full Text] [Related]  

  • 7. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
    Giro C; Berger B; Bölke E; Ciernik IF; Duprez F; Locati L; Maillard S; Ozsahin M; Pfeffer R; Robertson AG; Langendijk JA; Budach W
    Radiother Oncol; 2009 Feb; 90(2):166-71. PubMed ID: 18977050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.
    Chan A; Teoh D; Sanghera P; Hartley A
    Radiother Oncol; 2009 Dec; 93(3):654. PubMed ID: 19524312
    [No Abstract]   [Full Text] [Related]  

  • 9. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
    Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
    Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F
    Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
    Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
    Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
    N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
    Bonomo P; Loi M; Desideri I; Olmetto E; Delli Paoli C; Terziani F; Greto D; Mangoni M; Scoccianti S; Simontacchi G; Francolini G; Meattini I; Caini S; Livi L
    Crit Rev Oncol Hematol; 2017 Dec; 120():98-110. PubMed ID: 29198343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.
    Selzer E; Liederer S; Lemaire C; Kren G; Radonjic D; Kornek G; Knocke T; Pötter R; Bachtiary B
    Strahlenther Onkol; 2011 Jun; 187(6):373-7. PubMed ID: 21603990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
    Habl G; Potthoff K; Haefner MF; Abdollahi A; Hassel JC; Boller E; Indorf M; Debus J
    BMC Cancer; 2013 Jul; 13():345. PubMed ID: 23855804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck.
    Villavicencio M; Granados-García M; Vilajosana E; Domínguez-Cherit J
    Int J Dermatol; 2017 Jun; 56(6):602-609. PubMed ID: 28247918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma.
    Zhu G; Lin JC; Kim SB; Bernier J; Agarwal JP; Vermorken JB; Thinh DHQ; Cheng HC; Yun HJ; Chitapanarux I; Lertsanguansinchai P; Reddy VA; He X
    BMC Cancer; 2016 Jan; 16():42. PubMed ID: 26817597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe cutaneous reaction during radiation therapy with concurrent cetuximab.
    Budach W; Bölke E; Homey B
    N Engl J Med; 2007 Aug; 357(5):514-5. PubMed ID: 17671265
    [No Abstract]   [Full Text] [Related]  

  • 19. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
    Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
    Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
    Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.